Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-19366.82%
operating margin TTM
-22815.23%
revenue TTM
N/A
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -11.89 |
| peg ratio | -11.48 |
| price to book ratio | 3.51 |
| price to sales ratio | 2,331.92 |
| enterprise value multiple | -11.26 |
| price fair value | 3.51 |
profitability ratios | |
|---|---|
| gross profit margin | 46.59% |
| operating profit margin | -22815.23% |
| pretax profit margin | -19314.09% |
| net profit margin | -19366.82% |
| return on assets | -27.9% |
| return on equity | -29.46% |
| return on capital employed | -34.81% |
liquidity ratio | |
|---|---|
| current ratio | 17.44 |
| quick ratio | 17.44 |
| cash ratio | 5.91 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 1,582.70 |
| cash conversion cycle | -1,582.70 |
| receivables turnover | 0.00 |
| payables turnover | 0.23 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | -59.26 |
| cash flow to debt ratio | -805.54 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.42 |
| cash per share | 6.05 |
| operating cash flow per share | -1.42 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -805.54 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -1,180.53 |
Frequently Asked Questions
When was the last time Enliven Therapeutics, Inc. (NASDAQ:ELVN) reported earnings?
Enliven Therapeutics, Inc. (ELVN) published its most recent earnings results on 13-11-2024.
What is Enliven Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Enliven Therapeutics, Inc. (NASDAQ:ELVN)'s trailing twelve months ROE is -29.46%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Enliven Therapeutics, Inc. (ELVN) currently has a ROA of -27.9%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ELVN's net profit margin stand at?
ELVN reported a profit margin of -19366.82% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ELVN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 17.44 in the most recent quarter. The quick ratio stood at 17.44, with a Debt/Eq ratio of 0.00.